Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Dexter

Showing results (21-30 of 132) with videos related to

Pageof 14
Sort By:
Journal of Trace Elements in Medicine and Biology : Organ of the Society for Minerals and Trace Elements (GMS)|February 27, 2015
Neurodegenerative diseases and therapeutic strategies using iron chelatorsRoberta J Ward, David T Dexter, Robert R Crichton
Journal of Neurochemistry|October 1, 2018
The histone deacetylase inhibitor nicotinamide exacerbates neurodegeneration in the lactacystin rat model of Parkinson's diseaseIan F Harrison, Nicholas M Powell, David T Dexter
Current Medicinal Chemistry|April 12, 2012
Chelating agents for neurodegenerative diseasesR J Ward, D T Dexter, R R Crichton
Journal of Neural Transmission (Vienna, Austria : 1996)|September 3, 2010
Brain iron metabolism and its perturbation in neurological diseasesRobert R Crichton, David T Dexter, Roberta J Ward
Journal of Molecular Neuroscience : MN|September 1, 2014
Calcium CaV1 channel subtype mRNA expression in Parkinson's disease examined by in situ hybridizationMichael J Hurley, Steve M Gentleman, David T Dexter
Neuroscience Letters|December 24, 2017
Pathological histone acetylation in Parkinson's disease: Neuroprotection and inhibition of microglial activation through SIRT 2 inhibitionIan F Harrison, Andrew D Smith, David T Dexter
Movement Disorders : Official Journal of the Movement Disorder Society|June 8, 2001
Chronic L-DOPA administration is not toxic to the remaining dopaminergic nigrostriatal neurons, but instead may promote their functional recovery, in rats with partial 6-OHDA or FeCl(3) nigrostriatal lesionsK P Datla, S B Blunt, D T Dexter
Neuroreport|February 22, 2008
Additive neuroprotection by metabotropic glutamate receptor subtype-selective ligands in a rat Parkinson's modelAnthony C Vernon, Martin J Croucher, David T Dexter
Frontiers in Bioscience (Scholar Edition)|May 12, 2015
Ageing, neuroinflammation and neurodegenerationRoberta J Ward, David T Dexter, Robert R Crichton
Advances in Neurology|January 1, 1993
Implications of alterations in trace element levels in brain in Parkinson's disease and other neurological disorders affecting the basal gangliaD T Dexter, J Sian, P Jenner, et al.
Pageof 14

Showing results (21-30 of 132) with videos related to

Sort By:
Pageof 14
Journal of Trace Elements in Medicine and Biology : Organ of the Society for Minerals and Trace Elements (GMS)|February 27, 2015
Neurodegenerative diseases and therapeutic strategies using iron chelatorsRoberta J Ward, David T Dexter, Robert R Crichton
Journal of Neurochemistry|October 1, 2018
The histone deacetylase inhibitor nicotinamide exacerbates neurodegeneration in the lactacystin rat model of Parkinson's diseaseIan F Harrison, Nicholas M Powell, David T Dexter
Current Medicinal Chemistry|April 12, 2012
Chelating agents for neurodegenerative diseasesR J Ward, D T Dexter, R R Crichton
Journal of Neural Transmission (Vienna, Austria : 1996)|September 3, 2010
Brain iron metabolism and its perturbation in neurological diseasesRobert R Crichton, David T Dexter, Roberta J Ward
Journal of Molecular Neuroscience : MN|September 1, 2014
Calcium CaV1 channel subtype mRNA expression in Parkinson's disease examined by in situ hybridizationMichael J Hurley, Steve M Gentleman, David T Dexter
Neuroscience Letters|December 24, 2017
Pathological histone acetylation in Parkinson's disease: Neuroprotection and inhibition of microglial activation through SIRT 2 inhibitionIan F Harrison, Andrew D Smith, David T Dexter
Movement Disorders : Official Journal of the Movement Disorder Society|June 8, 2001
Chronic L-DOPA administration is not toxic to the remaining dopaminergic nigrostriatal neurons, but instead may promote their functional recovery, in rats with partial 6-OHDA or FeCl(3) nigrostriatal lesionsK P Datla, S B Blunt, D T Dexter
Neuroreport|February 22, 2008
Additive neuroprotection by metabotropic glutamate receptor subtype-selective ligands in a rat Parkinson's modelAnthony C Vernon, Martin J Croucher, David T Dexter
Frontiers in Bioscience (Scholar Edition)|May 12, 2015
Ageing, neuroinflammation and neurodegenerationRoberta J Ward, David T Dexter, Robert R Crichton
Advances in Neurology|January 1, 1993
Implications of alterations in trace element levels in brain in Parkinson's disease and other neurological disorders affecting the basal gangliaD T Dexter, J Sian, P Jenner, et al.
Pageof 14